Global Viscosupplementation System Market 2025-2035

Description

List of Tables

Viscosupplementation System Market Size, Share & Trends Analysis Report by Product (Single-Injection, Three-Injection, and Five-Injection) By Application (Knee, Hip, Ankle, and Others), Forecast Period (2025-2035)

Industry Overview

Viscosupplementation system market was valued at $5.7 billion in 2024 and is projected to reach $11.1 billion by 2035, growing at a CAGR of 6.3% during the forecast period (2025-2035). The global viscosupplementation system market is witnessing significant growth driven by the rising prevalence of osteoarthritis and an increasing preference for minimally invasive treatment options. Advancements in hyaluronic acid-based formulations have improved product efficacy, enhancing patient outcomes and acceptance. Companies such as Anika Therapeutics and Fidia Farmaceutici are actively expanding their product portfolios to cater to diverse joint applications. Additionally, growing awareness among orthopedic specialists about joint preservation therapies is boosting market adoption. The introduction of single-injection systems has further simplified treatment protocols, encouraging broader clinical use.

Market Dynamics

Rising Adoption of Single-Injection Viscosupplementation Systems

The market is witnessing a growing preference for single-injection viscosupplementation systems owing to their convenience and reduced patient discomfort. This trend is driven by healthcare providers seeking efficient treatment options for osteoarthritis and joint pain management. Companies like Zimmer Biomet have expanded their product portfolio to include single-injection formulations, which streamline clinical procedures and improve patient compliance. Enhanced patient experience and shorter procedure times are key factors fueling market growth.

Expansion in Knee Osteoarthritis Applications

Knee osteoarthritis remains the largest application segment, reflecting increasing cases of degenerative joint diseases among aging populations. Advanced viscosupplementation products are being tailored specifically for knee joints to optimize mobility and pain relief. For instance, Fidia Farmaceutici offers innovative hyaluronic acid-based formulations designed for targeted knee therapy. Growing awareness among patients and physicians about non-surgical treatment options is further supporting the uptake of these products globally.

Market Segmentation

Based on the product, the market is segmented into single-injection, three-injection, and five-injection.
Based on the application, the market is segmented into knee, hip, ankle, and others.

Three-Injection Systems Segment to Lead the Market with the Largest Share

The global viscosupplementation system Market is expanding as three-injection treatment regimens gain preference among clinicians for enhanced joint lubrication and sustained relief. Products such as Synvisc-One by Sanofi offer multi-dose options that improve patient adherence and clinical outcomes. The structured injection schedule allows for more consistent therapeutic effects, which is particularly valued in chronic osteoarthritis management. Increasing physician confidence in the efficacy of these regimens is driving adoption across key markets. Companies are also focusing on educating healthcare providers about optimized injection protocols to maximize patient satisfaction.

Knee: A Key Segment in Market Growth

The knee joint remains the largest application segment in the Viscosupplementation System Market owing to its high susceptibility to osteoarthritis. Products like Hyalgan by Fidia Farmaceutici are widely used for knee viscosupplementation, offering pain relief and improved mobility. The rising incidence of knee osteoarthritis, particularly among aging populations, is fueling demand for targeted treatments. Orthopedic specialists increasingly recommend viscosupplementation as a non-surgical option, further expanding its use. Market players are also introducing advanced hyaluronic acid formulations specifically for knee applications to enhance therapeutic outcomes.

Regional Outlook

The global viscosupplementation system market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Increasing Incidence of Osteoarthritis and Related Disorders in Europe

The European viscosupplementation market is expanding as clinicians increasingly prefer targeted joint therapies for osteoarthritis and related disorders. Innovations in hyaluronic acid-based formulations have improved treatment outcomes and patient comfort. Companies such as Fidia Farmaceutici are introducing advanced products specifically designed for knee and hip applications, enhancing therapeutic efficacy. Rising awareness among healthcare professionals about non-surgical joint management is further supporting adoption. Additionally, favorable reimbursement policies in key countries such as Germany and France are encouraging broader utilization. The combination of product innovation and supportive healthcare frameworks is driving steady market growth across Europe.

North America Region Dominates the Market with a Major Share

In North America, the market is advancing owing to the high prevalence of degenerative joint conditions and the preference for minimally invasive treatments. Leading companies like Zimmer Biomet have launched single-injection viscosupplementation systems, offering convenience and reduced procedural times. Enhanced patient compliance and positive clinical outcomes are encouraging widespread adoption among orthopedic practitioners. Investments in research and development continue to introduce next-generation formulations with improved durability. Furthermore, growing patient awareness and accessibility of treatment options are reinforcing market expansion.

Market Players Outlook

The major companies operating in the global viscosupplementation system market include Anika Therapeutics, Inc., Bioventus LLC, Fidia Farmaceutici S.p.A., Sanofi S.A., Zimmer Biomet Holdings, Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In February 2025, Seikagaku Corp. reported ongoing investment and progress in innovative hyaluronic acid (HA) injections for viscosupplementation, focusing on improving the efficacy and duration of joint lubrication. Notably, Seikagaku initiated Phase III clinical studies in Japan for Gel-One, a cross-linked hyaluronate hydrogel injection designed for osteoarthritis of the knee and hip, which aims to provide long-term pain relief and remain in the joint cavity for extended periods. This product leverages Seikagaku's unique cross-linking technology and has shown promise for superior durability compared to other HA monotherapies.
In January 2024, Zimmer Biomet globally launched its VISCO-3 three-injection viscosupplementation system targeting moderate-stage knee osteoarthritis and providing significant long-term pain relief and enhanced mobility. This product consists of three separate injections of high molecular weight sodium hyaluronate, performed over consecutive weeks as a non-surgical therapy for osteoarthritis patients who prefer predictable, extended relief and wish to avoid joint replacement.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global viscosupplementation system market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023501

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Viscosupplementation System Market Sales Analysis - Product | Application| ($ Million)
Viscosupplementation System Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Viscosupplementation System Market Trends
- 2.2.2. Market Recommendations
2.3. Porter's Five Forces Analysis for the Viscosupplementation System Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Viscosupplementation System Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Viscosupplementation System Market: Impact Analysis
3.3. Market Opportunities

4. Competitive Landscape

4.1. Competitive Dashboard - Viscosupplementation System Market Revenue and Share by Manufacturers
Viscosupplementation System Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Anika Therapeutics, Inc.
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Bioventus LLC
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Fidia Farmaceutici S.p.A.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Sanofi S.A.
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Zimmer Biomet Holdings, Inc.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Viscosupplementation System Market Sales Analysis by Product ($ Million)

5.1. Single-Injection
5.2. Three-Injection
5.3. Five-Injection

6. Global Viscosupplementation System Market Sales Analysis by Application ($ Million)

6.1. Knee
6.2. Hip
6.3. Ankle
6.4. Others (Shoulder, Spine)

7. Regional Analysis

7.1. North American Viscosupplementation System Market Sales Analysis - Product | Application | Country ($ Million)
Macroeconomic Factors for North America
- 7.1.1. United States
- 7.1.2. Canada
7.2. European Viscosupplementation System Market Sales Analysis - Product | Application | Country ($ Million)
Macroeconomic Factors for Europe
- 7.2.1. UK
- 7.2.2. Germany
- 7.2.3. Italy
- 7.2.4. Spain
- 7.2.5. France
- 7.2.6. Russia
- 7.2.7. Rest of Europe
7.3. Asia-Pacific Viscosupplementation System Market Sales Analysis - Product | Application | Country ($ Million)
Macroeconomic Factors for Asia-Pacific
- 7.3.1. China
- 7.3.2. Japan
- 7.3.3. South Korea
- 7.3.4. India
- 7.3.5. Australia & New Zealand
- 7.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 7.3.7. Rest of Asia-Pacific
7.4. Rest of the World Viscosupplementation System Market Sales Analysis - Product | Application | Country ($ Million)
Macroeconomic Factors for Rest of the World
- 7.4.1. Latin America
- 7.4.2. Middle East and Africa

8. Company Profiles

8.1. Allergan plc
- 8.1.1. Quick Facts
- 8.1.2. Company Overview
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategies
8.2. Anika Therapeutics, Inc.
- 8.2.1. Quick Facts
- 8.2.2. Company Overview
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategies
8.3. Avanos Medical, Inc.
- 8.3.1. Quick Facts
- 8.3.2. Company Overview
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategies
8.4. Bausch Health Companies, Inc.
- 8.4.1. Quick Facts
- 8.4.2. Company Overview
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategies
8.5. Bioventus LLC
- 8.5.1. Quick Facts
- 8.5.2. Company Overview
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategies
8.6. Chugai Pharmaceutical Co., Ltd.
- 8.6.1. Quick Facts
- 8.6.2. Company Overview
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategies
8.7. F. Hoffmann-La Roche Ltd.
- 8.7.1. Quick Facts
- 8.7.2. Company Overview
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategies
8.8. Ferring Pharmaceuticals B.V.
- 8.8.1. Quick Facts
- 8.8.2. Company Overview
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategies
8.9. Fidia Farmaceutici S.p.A.
- 8.9.1. Quick Facts
- 8.9.2. Company Overview
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategies
8.10. IBSA Institut Biochimique S.A.
- 8.10.1. Quick Facts
- 8.10.2. Company Overview
- 8.10.3. Product Portfolio
- 8.10.4. Business Strategies
8.11. LG Chem, Ltd.
- 8.11.1. Quick Facts
- 8.11.2. Company Overview
- 8.11.3. Product Portfolio
- 8.11.4. Business Strategies
8.12. Lifecore Biomedical, LLC
- 8.12.1. Quick Facts
- 8.12.2. Company Overview
- 8.12.3. Product Portfolio
- 8.12.4. Business Strategies
8.13. MHRA/Bio-Polymer GmbH & Co. KG
- 8.13.1. Quick Facts
- 8.13.2. Company Overview
- 8.13.3. Product Portfolio
- 8.13.4. Business Strategies
8.14. OrthogenRx, Inc.
- 8.14.1. Quick Facts
- 8.14.2. Company Overview
- 8.14.3. Product Portfolio
- 8.14.4. Business Strategies
8.15. Sanofi S.A.
- 8.15.1. Quick Facts
- 8.15.2. Company Overview
- 8.15.3. Product Portfolio
- 8.15.4. Business Strategies
8.16. Seikagaku Corp.
- 8.16.1. Quick Facts
- 8.16.2. Company Overview
- 8.16.3. Product Portfolio
- 8.16.4. Business Strategies
8.17. Smith & Nephew plc
- 8.17.1. Quick Facts
- 8.17.2. Company Overview
- 8.17.3. Product Portfolio
- 8.17.4. Business Strategies
8.18. Teva Pharmaceutical Industries Ltd.
- 8.18.1. Quick Facts
- 8.18.2. Company Overview
- 8.18.3. Product Portfolio
- 8.18.4. Business Strategies
8.19. Wellchem Pharma Pvt. Ltd.
- 8.19.1. Quick Facts
- 8.19.2. Company Overview
- 8.19.3. Product Portfolio
- 8.19.4. Business Strategies
8.20. Zimmer Biomet Holdings, Inc.
- 8.20.1. Quick Facts
- 8.20.2. Company Overview
- 8.20.3. Product Portfolio
- 8.20.4. Business Strategies